1. China Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Chaoju Eye Care Holdings Ltd.

Chaoju Eye Care Holdings Ltd.

2.33
HKD
+0.00
(-0.21%)
1.91BMarket Cap
Mar 30Next Earn
Chaoju Eye Care Holdings Ltd.
HKEX:2219
(Hong Kong Exchange)

Recent

price

2.33

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.92
1.04
1.16
1.6
1.4
1.97
2.04
1.96
- -
Revenue per Share
0.06
0.11
0.18
0.26
0.27
0.33
0.28
0.26
- -
Basic EPS, GAAP
-0.01
0.17
0.29
0.3
0.21
0.41
0.32
0.16
- -
Free Cash Flow per Basic Share
- -
- -
0.05
0.18
0.09
0.16
0.39
0.11
- -
Dividend per Share
0.6
0.76
1.07
2.98
3.24
3.43
3.35
3.46
3.46
Book Value per Share
0.47
0.63
0.95
2.86
2.94
2.89
2.84
3.03
3.03
Tangible Book Value per Share
688
688
688
625
706
696
689
694
694
Basic Weighted Avg Shares
633
715
794
998
990
1,370
1,405
1,360
- -
Sales/Revenue/Turnover
11.82
15.38
21.71
21.34
21.39
21.72
18.18
18.56
- -
Operating Margin (%)
72
76
77
84
99
123
144
148
- -
Depreciation Expense
39
76
124
162
188
229
195
183
- -
Net Income, GAAP
38.39
23.07
23.53
25.14
23.39
26.24
29.12
30.73
- -
Effective Tax Rate (%)
6.12
10.59
15.63
16.21
18.96
16.72
13.88
13.49
- -
Profit Margin (%)
70
142
343
1,693
1,570
1,387
1,369
1,265
1,265
Working Capital
200
163
106
132
143
152
177
199
199
LT Debt
449
554
764
2,128
2,298
2,378
2,326
2,407
2,407
Total Equity
- -
10.47
15.26
9.84
6.76
8.98
7.04
6.72
- -
Return on Invested Capital (%)
- -
12.17
16.12
10.82
8.39
9.7
8.26
7.63
- -
Return on Capital (%)
- -
16.23
19.72
11.38
8.58
9.88
8.34
7.77
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
41
44
38
LT Borrowings
34
34
35
LT Finance Leases
143
175
164
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
691
696
694
Market Capitalization
1,850
1,810
1,715

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,708
1,643
1,641
Cash, Cash Equivalents & STI
1,540
1,475
1,485
Accounts Receivable, Net
74
70
69
Inventories
40
47
42
Total Current Liabilities
339
394
376
Payables & Accruals
- -
- -
- -
ST Debt
41
44
38
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.3%
3.47%
Free Cash Flow
- -
-0.89%
-48.38%
Net Income, GAAP
- -
9.51%
-5.96%
Sales/Revenue/Turnover
- -
12.52%
-3.21%
Total Cash Common Dividend
- -
67.34%
-71.82%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,370
2024
- -
- -
1,405
2025
- -
- -
1,360

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.33
2024
- -
- -
0.28
2025
- -
- -
0.26

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.16
2024
- -
- -
0.39
2025
- -
- -
0.11
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Chaoju Eye Care Holdings Limited (2219.HK) operates a network of 31 ophthalmic hospitals and 29 optical centers across seven provinces, municipalities and autonomous regions in China, primarily in North China including Inner Mongolia, adjacent regions, Zhejiang, Jiangsu, Ningxia and Beijing; the company provides consumer ophthalmic services including refractive correction with presbyopia correction, myopia prevention and control, dry eye syndrome treatment, oculoplastic procedures and optical products and services not covered by public health insurance, as well as basic ophthalmic services covering cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases mostly reimbursable under insurance programs, plus minor sales of equipment and medical consumables. Founded in 1988 in Baotou, Inner Mongolia, and headquartered at 24/F, East Zone, Block A, Shouke Building, No. 14 Yard, West 3rd Ring South Road, Fengtai District, Beijing, China, the group targets patients seeking specialized eye care through its clustered model in key regions like western and eastern Inner Mongolia, with inpatient and outpatient services supported by 1,500 full-time medical professionals including 320 physicians. In recent developments, the company announced acquisitions in 2025 including full buyout of Ningbo Boshi Eye Hospital for RMB14 million valuing it at RMB38 million and 70% stake in Wuzhong Yunshikang Eye Hospital for RMB5 million valuing it at RMB7.14 million to deepen presence in Zhejiang and Ningxia amid revenue contraction and profit decline in 2024; it maintains capital commitments of RMB69.3 million as of June 2025 for hospital renovations, equipment procurement and these deals, while subscribing RMB410 million in low-risk structured deposits for treasury management and planning network expansion in North China and Yangtze River Delta via further acquisitions and new builds, reporting 31 hospitals and 29 centers as of June 30, 2025 with revenue of RMB698.3 million for H1 2025 down 4.9% year-over-year.